Literature DB >> 24756006

An update on management of Budd-Chiari syndrome.

Andrea Mancuso1.   

Abstract

The topic of this paper is to report an update on management of Budd-Chiari syndrome (BCS). Actually, the flow-chart of BCS management comes from experts opinion and is not evidence-based due to the rarity of BCS. Management of BCS follows a step-wise strategy. Anticoagulation and medical therapy should be the first line treatment. Revascularization or TIPS in case of no response to medical therapy. OLT as a rescue therapy. Surgery has limited but important space, especially in cases with high inferior vena cava obstruction not suitable for endovascular treatment. However, no clear indication can actually be given about the timing of different treatments. Moreover, there is some concern about treatment of some subgroup of patients, especially regarding the risk of recurrence after liver transplantation. This paper propose a new algorithm of BCS management suggesting an earlier therapeutic approach when clinical signs are evident.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756006

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  5 in total

1.  Portal vein aneurysm associated with Budd-Chiari syndrome treated with transjugular intrahepatic portosystemic shunt: a case report.

Authors:  Jiaywei Tsauo; Xiao Li
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist's Perspective.

Authors:  Andrea Mancuso
Journal:  J Transl Int Med       Date:  2017-12-29

3.  Ultrasound-guided direct intrahepatic portosystemic shunt in patients with Budd-Chiari syndrome: Short- and long-term results.

Authors:  Adam Hatzidakis; Nikolaos Galanakis; Elias Kehagias; Dimitrios Samonakis; Mairi Koulentaki; Erminia Matrella; Dimitrios Tsetis
Journal:  Interv Med Appl Sci       Date:  2017-06

4.  Hypoxia-inducible Factor may Induce the Development of Liver Fibrosis in Budd-Chiari Syndrome by Regulating CD248/endosialin Expression: A Hypothesis.

Authors:  Ye Tian; Han Deng; Lei Han; Sijun Hu; Xingshun Qi
Journal:  J Transl Int Med       Date:  2018-06-26

5.  Pregnancy in Budd-Chiari Syndrome: Case Report and Proposed Risk Score.

Authors:  Waltraut M Merz; Anna M Rüland; Valeria Hippe; Bernd Poetzsch; Carsten Meyer; Joerg M Pollok; Ulrich Gembruch; Jonel Trebicka
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.